Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis
Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis
复制标题
DOI：
10.1007/s00432-022-04133-8
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
Tao Li
中科院分区：
文献类型：
--
作者：
Zi-Niu Ding;Guang-Xiao Meng;Jun-Shuai Xue;Lun-Jie Yan;Hui Liu;Yu-Chuan Yan;Zhi-Qiang Chen;Jian-Guo Hong;Dong-Xu Wang;Zhao-Ru Dong;Tao Li
Immune checkpoint inhibitors (ICIs) have been explored as first-line treatment in various types of previously untreatable malignancies, while limited evidence is available on the management of hepatitis B virus (HBV) in patients undergoing immunotherapy. We systematically reviewed data concerning challenges of hepatic adverse events including HBV reactivation and hepatitis in patients with chronic HBV infection undergoing immunotherapy.A systematic search was conducted in Medline, web of science, Embase and Cochrane library up to May 31, 2022. Studies reporting the safety profile of ICIs in patients with HBV infection were eligible. Meta-analyses were conducted to generate odds ratios (ORs) with 95% confidence intervals (CIs).A total of 13 studies including 2561 patients were included for meta-analysis. The overall incidence rates of HBV reactivation in patients with chronic HBV infection and past HBV infection were 1.0% (95% CI 0-3%) and 0% (95% CI 0-0%), respectively. Among patients with chronic HBV infection, the incidence rates of HBV reactivation were 1.0% (95% CI 0-2%) and 10.0% (95% CI 4-18%) for patients with and without antiviral prophylaxis, respectively. Patients with chronic HBV infection were at a higher risk of HBV reactivation compared with those with past HBV infection [OR = 8.69, 95% CI (2.16-34.99). Antiviral prophylaxis significantly reduced the risk of HBV reactivation [OR = 0.12, 95% CI (0.02-0.67) and HBV-associated hepatitis [OR = 0.05, 95% CI (0.01-0.28) in patients with chronic HBV infection.Prophylactic antiviral therapy should be administered to patients with chronic HBV infection undergoing anticancer immunotherapy. Patients with past HBV infection are at lower risk of HBV reactivation compared with those with chronic HBV infection, they could be initiated with antiviral prophylaxis or monitored with the intent of on-demand antiviral therapy.
